Joe FitzPatrick

The measures include:

• £1.9 million to support people in prison on prescribed Opiate Substitution Treatment (OST) to switch to a new longer-acting form called buvidal
• £150,000 for an enhanced offer of residential rehab to people leaving prison during the pandemic to support their recovery and to reduce the pressure on local services
• widening the availability of overdose reversal drug Naloxone while measures to tackle coronavirus remain in place

Joe FitzPatrick, public health minister, said: “While this public health crisis is ongoing, we must not lose sight of the fact there continues to be a significant number of highly vulnerable individuals who are at great risk of harm as a result of alcohol and drug use, who continue to need a wide range of help and support.

“Buvidal is an alternative to methadone or buprenorphine tablets which is administered by a seven or 28-day injectable dose, rather than daily administration. By making this available to people in prisons, we will support continuity of care, while reducing the need for daily contact and reducing pressure on our front line prison officers and NHS staff.

“Furthermore, a high proportion of those leaving or about to leave prison will require support for their recovery from problem alcohol or drug. Funding to pay for additional residential rehabilitation places will support their recovery and to reduce the pressure on local services.

“I welcome the Lord Advocate’s statement of prosecution policy in respect of the distribution of naloxone during the period of disruption caused by COVID-19. This will help to ensure that we can continue to support those affected by drug use and keep them safe.”

• Read all of our articles relating to COVID-19 here.